Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 14, 485 - 487 (2008)
doi:10.1038/nm0508-485
-adrenergic signaling in heart failure—adapt or die
Thomas Eschenhagen1
- Thomas Eschenhagen is at the Institute of Experimental and Clinical Pharmacology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.
e-mail: t.eschenhagen@uke.uni-hamburg.de
Abstract
About 25% of the African-American population carries a gene variant that seems to protect against heart failure. The findings may have implications for the use of 
-blockers (pages 510–517).
A report in this issue of Nature Medicine1 identifies a gene variant that seems to protect against the progression of heart failure. The gene, GRK5, encodes a G protein–coupled receptor kinase (GRK) that participates in signaling through -adrenergic receptors, the targets of -blockers.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
BRAF Mutations Are Common Somatic Events in Melanocytic Nevi 1Journal of Investigative Dermatology Original Article
A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failureNature Medicine Article (01 May 2008)
β 1 -adrenergic receptor polymorphisms confer differential function and predisposition to heart failureNature Medicine Article (01 Oct 2003)
